BeiGene's Zanubrutinib Fails To Meet Efficacy Endpoints In Mid-Stage COVID-19 Study

by Vandana Singh, Benzinga Editor

April 8, 2021 8:29 AM | 1 min read |

BeiGene Ltd BGNE has announced data from Phase 2 trial evaluating Brukinsa (zanubrutinib) in hospitalized COVID-19 patients, requiring supplemental oxygen without mechanical ventilation.
The study did not meet the co-primary efficacy endpoints of respiratory failure-free survival or reduction in days on oxygen compared to placebo.
There were no new or additional safety signals for zanubrutinib identified in the trial.
BeiGene expects to submit these data for scientific presentation or publication in the future.
Brukinsa is a small molecule inhibitor of Bruton's tyrosine kinase (BTK).
Price Action: BGNE shares closed 2.3% lower at $321.60 on Wednesday.

Posted In: Biotech News Health Care FDA General Briefs Covid-19 Phase 2 Trial

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.